These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16337261)

  • 21. The antidepressant drugs fluoxetine and duloxetine produce anxiolytic-like effects in a schedule-induced polydipsia paradigm in rats: enhancement of fluoxetine's effects by the α2 adrenoceptor antagonist yohimbine.
    Prus AJ; Mooney-Leber SM; Berquist MD; Pehrson AL; Porter NP; Porter JH
    Behav Pharmacol; 2015 Aug; 26(5):489-94. PubMed ID: 26154437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.
    Nikiforuk A; Kos T; Wesołowska A
    Psychopharmacology (Berl); 2011 Oct; 217(3):411-8. PubMed ID: 21499701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A
    Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.
    Troelsen KB; Nielsen EØ; Mirza NR
    Psychopharmacology (Berl); 2005 Oct; 181(4):741-50. PubMed ID: 16032412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
    Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
    Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
    Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HT
    Zhang LM; Wang XY; Zhao N; Wang YL; Hu XX; Ran YH; Liu YQ; Zhang YZ; Yang RF; Li YF
    Br J Pharmacol; 2017 May; 174(9):769-780. PubMed ID: 27882537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
    Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo.
    Kask A; Mutulis F; Muceniece R; Pähkla R; Mutule I; Wikberg JE; Rägo L; Schiöth HB
    Endocrinology; 1998 Dec; 139(12):5006-14. PubMed ID: 9832440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
    Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
    Dekeyne A; Brocco M; Adhumeau A; Gobert A; Millan MJ
    Psychopharmacology (Berl); 2000 Sep; 152(1):55-66. PubMed ID: 11041316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
    Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
    Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor.
    Nozawa D; Okubo T; Ishii T; Kakinuma H; Chaki S; Okuyama S; Nakazato A
    Bioorg Med Chem; 2007 Mar; 15(5):1989-2005. PubMed ID: 17234422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of 5-HT2C and 5-HT1A receptors of the basolateral nucleus of the amygdala in the anxiolytic effect of chronic antidepressant treatment.
    Vicente MA; Zangrossi H
    Neuropharmacology; 2014 Apr; 79():127-35. PubMed ID: 24275045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
    Yamaguchi T; Tsujimatsu A; Kumamoto H; Izumi T; Ohmura Y; Yoshida T; Yoshioka M
    J Ethnopharmacol; 2012 Sep; 143(2):533-9. PubMed ID: 22819689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.
    Beyer CE; Lin Q; Platt B; Malberg J; Hornby G; Sullivan KM; Smith DL; Lock T; Mitchell PJ; Hatzenbuhler NT; Evrard DA; Harrison BL; Magolda R; Pangalos MN; Schechter LE; Rosenzweig-Lipson S; Andree TH
    Br J Pharmacol; 2009 May; 157(2):307-19. PubMed ID: 19338583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidepressant/anxiolytic potential and adverse effect liabilities of melanin-concentrating hormone receptor 1 antagonists in animal models.
    Chaki S; Shimazaki T; Nishiguchi M; Funakoshi T; Iijima M; Ito A; Kanuma K; Sekiguchi Y
    Pharmacol Biochem Behav; 2015 Aug; 135():154-68. PubMed ID: 26044968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive allosteric modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action.
    Fitzpatrick CM; Larsen M; Madsen LH; Caballero-Puntiverio M; Pickering DS; Clausen RP; Andreasen JT
    Behav Pharmacol; 2016 Sep; 27(6):549-55. PubMed ID: 27341500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist.
    Gao N; Tiliwaerde M; Zheng W; Xiong J; Li X; Jin Z
    Neuropharmacology; 2021 Jan; 182():108376. PubMed ID: 33122031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.